SCHEMBL7559226

SCHEMBL7559226

O=Cc1cccc(CN2CCOCC2)c1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.61
ALOX15 P16050 1/20 0.61
HSD17B10 Q99714 1/20 0.61
ERN1 O75460 2/20 0.54
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 2/20 0.52
GAA P10253 2/20 0.52
KMT2A Q03164 2/20 0.52
LMNA P02545 1/20 0.52
MAPT P10636 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
CYP2A13 Q16696 6/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
CXCR4 P61073 1/20 0.44
NCF1 P14598 1/20 0.43
POLB P06746 1/20 0.43
CTSB P07858 1/20 0.43
METAP2 P50579 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23926340 0.86 ERN1 (0.46) CYP2C9ALOX15HSD17B10ERN1ALDH1A1
SCHEMBL5075020 0.84 CYP2A13 (0.58) CYP2C9ALOX15HSD17B10ERN1ALDH1A1
SCHEMBL23926337 0.83 SIGMAR1 (0.48) CYP2C9ALOX15HSD17B10ERN1ALDH1A1
SCHEMBL29417692 0.82 CYP2A13 (0.56) CYP2C9ALOX15HSD17B10ERN1ALDH1A1
SCHEMBL19603399 0.82 CYP2A13 (0.56) CYP2C9ALOX15HSD17B10ERN1ALDH1A1
SCHEMBL17724305 0.82 CYP2A13 (0.56) CYP2C9ALOX15HSD17B10ERN1ALDH1A1
SCHEMBL16243516 0.79 CYP2A13 (0.49) CYP2C9ALOX15HSD17B10ERN1ALDH1A1
SCHEMBL16119943 0.78 ERN1 (0.53) CYP2C9ALOX15HSD17B10ERN1ALDH1A1
SCHEMBL3086221 0.78 ERN1 (0.62) CYP2C9ALOX15HSD17B10ERN1ALDH1A1
SCHEMBL19603394 0.78 CYP2A13 (0.45) CYP2C9ALOX15HSD17B10ERN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168408-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2023-04-26 EP disclosed
CN-115667256-A Compounds for treating diseases and methods of treating diseases 艾特里提治疗有限公司 2023-01-31 CN disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed
EP-1169269-A1 EXTRACTION OF METAL SALTS FROM AQUEOUS SOLUTIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2002-01-09 EP disclosed
WO-2000058225-A1 EXTRACTION OF METAL SALTS FROM AQUEOUS SOLUTIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155547-B1 Compounds for and methods of treating diseases HTT, SNCA, PARK7 CYP2C9 4492/4885ALOX15 214/4885HSD17B10 1114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.